• Most Popular
  • Most Shared

Bayer sees eye drug peak sales 250-500 mln euros

Fri Aug 3, 2007 2:59am EDT

Stocks

   

FRANKFURT, Aug 3 (Reuters) - German drugs and chemicals group Bayer BAYG.DE said on Friday it expected peak sales potential of its VEGF Trap-Eye drug at between 250 million and 500 million euros ($343 million-$685 million).

Bayer and and U.S. biotech partner Regeneron Pharmaceuticals (REGN.O) have launched a large clinical trial to try to show their eye drug is as good as Genentech's DNA.N Lucentis.

((Reporting by Frank Siebelt, writing by Mantik Kusjanto; Reuters Messaging: mantik.kusjanto.reuters.com@reuters.net; E-mail: mantik.kusjanto@reuters.com; +49 69 7565 1203))

($1=.7295 Euro) Keywords: BAYER REGENERON/VEGF

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nFRK013069


More from Reuters

Photo

AIG executive resigns over pay limits

NEW YORK (Reuters) - A top executive at American International Group Inc has resigned because of pay curbs imposed by the Obama Administration's pay czar, the insurer said on Wednesday.

» More Top News
A security camera sits on a building in New York City March 6, 2008. REUTERS/Joshua Lott

Trial run in Times Square

Critics say the Sept. 11 trials will endanger America's most populated city. Will a New Year's Eve plan hold up as New York's security template?  Full Article 

U.S.
People walk past a branch of Bank of America in New York's financial district April 28, 2009. REUTERS/Brendan McDermid
Rolfe Winkler:

Move your money

Boycotting "too big to fail" banks is a great idea -- so long as investors remember that banks aren't the only ones responsible for the crisis.  Full Article 

    Commentary